Goście specjalni
Prof. Alexander M. M. Eggermont, MD, PhD
Prof. Alexander M.M. Eggermont, MD, PhD is an internationally recognized expert in surgical oncology, immunotherapy, melanoma, sarcoma and cancer drug development.
He currently holds roles as Proferssor of Immunotherapy at the university Medical Center Utrecht and as Chief Scientific Officer at the Princess Máxima Center for Pediatric Oncology, the Netherlands; Professor of Oncology (Classe Exceptionelle) at Paris-Saclay University, France; Coordinator, Comprehensive Cancer Center Program for Deutsche KrebsHilfe; and Board of the Comprehensive Cancer Center Munich of the Technical University Munich and the Ludwig Maximiliaan University Munich, Germany.
Prof. Eggermont was previously Director General of Gustave Roussy Comprehensive Cancer Center, Villejuif, France (2010–2019); and Professor of Surgical Oncology (2003–2016) and Endowed Professor of International Networking in Cancer Research (2011–2018) at Erasmus University MC, Rotterdam, the Netherlands. He holds a PhD in tumor immunology from Erasmus University and is Fellow of the National Institutes of Health’s National Cancer Institute (NIH-NCI). Prof. Eggermont has served as President of ECCO, President of the EORTC, was a member of the Board of Directors of ASCO, served on the Editorial Board of the Journal of Clinical Oncology, and is currently Editor-in-Chief of the European Journal of Cancer. Prof. Eggermont has published more than 1000 peer-reviewed papers and his expertise has been acknowledged by many professional awards throughout his career.
Prof. Mario Mandalà
Prof. Mario Mandalà received his medical degree from the Faculty of Medicine, Catholic University of Rome, Italy. He completed residency trainings in Medical Oncology and Haematology and since then he has consistently been active in medical research. He is currently associate professor of Medical Oncology at the University of Perugia. In this position, he coordinates prospective outcome research projects and several clinical trials investigating new therapeutic strategies (including target therapies and immunotherapies) in melanoma and gastrointestinal cancer patients.
He was recently appointed Coordinator of the Mucosal and Ocular Melanoma Section of the Italian Rare Cancers Network.
Since 2011, he chaired the scientific and organizing committees of the Clinical and Translational Research Working Group of the Italian Melanoma Intergroup (IMI). Since 2019 Prof. Mandalà is President Elect of IMI. Since 2021 he is Secretary of the EORTC melanoma group.
He is full member of the European Society of Medical Oncology. He is Reviewer for several scientific journals, including Lancet Oncology, Cancer, British Journal of Cancer, Journal of Clinical Oncology, European journal of cancer, Annals of Oncology, Cancer Treatment Review, Journal of Thrombosis and Haemostasis, Thrombosis and Haemostasis, Arteriosclerosis-Thrombosis and Vascular Biology, Critical Reviews in Oncology and Haematology. He has authored more than 190 publications and his major scientific interests are clinical and translational research on melanoma, gastrointestinal cancer and thromboembolic complications in cancer patients. Since 2008, he gave major contributions in ESMO, AIOM and ISTH clinical practice guidelines on the management of venous thromboembolism and solid tumours.